ReviewPharmaceuticals (Basel, Switzerland)2025
Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms.
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biofilm-mediated antibiotic tolerance in bacterial pathogens: Integrated molecular networks and novel therapeutic avenues.Virulence · 2026Review
- Article
- Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance.International journal of molecular sciences · 2026Review
- Next-Generation Strategies for Controlling Foodborne Pathogens: Precision Antimicrobials, Biofilm Disruption, and Emerging Molecular Interventions.Foods (Basel, Switzerland) · 2026Review
- Phage enabled precision drug delivery: dual function platforms for therapeutics and genetic cargo transport.Frontiers in microbiology · 2026Review
- Precision bacteriophage therapy for multidrug-resistant recurrent urinary tract infections: From biological rationale to clinical translation in Taiwan.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial biofilms pose a substantial challenge in healthcare and industrial and environmental settings because of their resilience and antibiotic resistance. Biofilm formation is a complex process involving microbial communities encased in an extracellular matrix that contributes to increased resistance and persistent infections. This review explores the emerging roles of bacteriophages and their derived enzymes as promising alternatives or adjunct therapies to combat bacterial biofilms. Bacteriophages, viruses that infect bacteria, exhibit marked specificity and diverse mechanisms for targeting and lysing bacterial cells within biofilms. Enzymes, including endolysins and depolymerases, have demonstrated efficacy in disrupting biofilm matrices. Moreover, the potential synergy between bacteriophages and antibiotics enhances their antimicrobial activity, providing a multifaceted approach for combating biofilm-associated infections. This review critically evaluates the current research, highlighting the successes and limitations of bacteriophage-based strategies in biofilm control, and underscores the potential of these alternatives in shaping future therapeutic interventions against biofilm-related bacterial infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.